HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors: Analysis on the Global Market by Product & Geography (2019-2023) - ResearchAndMarkets.com

DUBLIN--()--The "HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market by Product and Geography - Global Forecast and Analysis 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The HER2 inhibitors market analysis considers sales from both monotherapy and combination therapy. The analysis also considers the sales of HER2 inhibitors in Asia, Europe, North America, and RoW.

In 2018, the monotherapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the presence of blockbuster drugs and fewer side-effects will play a significant role in the monotherapy segment to maintain its market position.

Also, the global HER2 inhibitors market report looks at factors such as the high prevalence of breast cancer and gastric cancer, recent approvals, and growing awareness about breast cancer. However, uncertainties in the introduction of Herceptin biosimilars, availability of alternative treatment options, and side effects of HER2 inhibitors may hamper the growth of the HER2 inhibitors industry over the forecast period.

High prevalence of breast cancer and gastric cancer

HER2 regulates cell growth, survival, and differentiation through multiple signal transduction pathways. Owing to the overexpression of HER2, the prevalence of several cancers including breast cancer, gastric and ovarian cancer is increasing. As there is a significant unmet need for effective HER2 inhibitors with fewer side-effects, pharmaceutical companies have significant scope for growth. This will lead to the expansion of the global HER2 inhibitors market at a CAGR of almost 9% during the forecast period.

Patient assistance programs

HER2 inhibitors are available at high costs, making it difficult for patients to purchase them. Thus, pharmaceutical sponsors are providing several patient assistance programs to reduce the cost burden, thus increasing patient adherence to HER2 inhibitors. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of several major players, the global HER2 inhibitors market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading HER2 inhibitors manufacturers, that include:

  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Puma Biotechnology Inc.

Also, the HER2 inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Key Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Comparison by product
  • Monotherapy - Market size and forecast 2018-2023
  • Combination therapy - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • RoW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

  • Patient assistance programs
  • Introduction of new diagnostics for breast cancer
  • Strategic alliances

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Puma Biotechnology Inc.

For more information about this report visit https://www.researchandmarkets.com/r/k9nsi5

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900